Bioactive peptides from venoms against glioma progression

Majc, Bernarda; Novak, Metka; Lah, Tamara T.; Križaj, Igor

doi:10.3389/fonc.2022.965882

Cited by 8 publications

(12 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…New treatments applying bioactive peptides may contribute to the multiplex targeting of GBM, particularly GSCs. Biopeptide-based therapeutics must use advanced GBM in vitro models, such as organoids, to explore combination approaches for clinically including bioactive peptides to standard cancer treatments 73 . Brain organoids have also been reported to be applied to the latest electric field therapy, and have shown good auxiliary value in evaluation of the efficacy and safety of electric field therapy 74 .…”

Section: Application Of Organoids In Gbm Researchmentioning

confidence: 99%

Development of glioblastoma organoids and their applications in personalized therapy

et al. 2023

View full text Add to dashboard Cite

Glioblastomas (GBMs) are the brain tumors with the highest malignancy and poorest prognoses. GBM is characterized by high heterogeneity and resistance to drug treatment. Organoids are 3-dimensional cultures that are constructed in vitro and comprise cell types highly similar to those in organs or tissues in vivo, thus simulating specific structures and physiological functions of organs. Organoids have been technically developed into an advanced ex vivo disease model used in basic and preclinical research on tumors. Brain organoids, which simulate the brain microenvironment while preserving tumor heterogeneity, have been used to predict patients’ therapeutic responses to antitumor drugs, thus enabling a breakthrough in glioma research. GBM organoids provide an effective supplementary model that reflects human tumors’ biological characteristics and functions in vitro more directly and accurately than traditional experimental models. Therefore, GBM organoids are widely applicable in disease mechanism research, drug development and screening, and glioma precision treatments. This review focuses on the development of various GBM organoid models and their applications in identifying new individualized therapies against drug-resistant GBM.

show abstract

Section: Application Of Organoids In Gbm Researchmentioning

confidence: 99%

Development of glioblastoma organoids and their applications in personalized therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For example, the expression of immune checkpoint proteins (PD-1 and PD-L1) can be suppressed by targeted peptides for increasing the immune response to kill tumor cells [144][145][146][147][148] . However, the high diversity of nature product peptides poses a challenge to the identification of the above-mentioned tumor neoantigens and bioactive peptides derived from venoms, which are produced by many kinds of organisms, such as plants, snakes, spiders and insects, and are found to interact with tumors and modulate the proliferation, migration, immune response of tumor cells, suggesting potential therapeutic agents for cancers [149][150][151][152][153][154][155] . Therapeutic peptides are promising candidates for treating various diseases, and more effective peptide drugs are required to address clinical demands.…”

Section: Perspective and Challenges Of Organoid-based High-throughput...mentioning

confidence: 99%

Integration of organoids in peptide drug discovery: rise of the high-throughput screening

Zhang

Shen

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Organoids are three-dimensional cell aggregates with near-physiologic cell behaviors and can undergo long-term expansion in vitro. They are amenable to high-throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid-based high-throughput screening has been extensively employed to discover small molecule drugs, encompassing the steps of generating organoids, examining efficient drugs in organoid cultures, and data assessment. Compared to small molecules, peptides are more straightforward to synthesize, can be modified chemically, and demonstrate a high degree of target specificity and low cytotoxicity. Therefore, they have emerged as promising carriers to deliver drugs to disease-associated targets, and could be efficient therapeutic drugs for various diseases. To date, organoids have been used to evaluate the efficacy of certain peptide agents; however, no organoid-based high-throughput screening of peptide drugs has been reported. Given the advantages of peptide drugs, there is an urgent need to establish organoid-based peptide high-throughput screening platforms. In this review, we discuss the typical approach of screening small-molecular drugs with the use of organoid cultures, as well as provide an overview of the studies that have incorporated organoids in peptide research. Drawing on the knowledge gained from small molecular screens, we explore the difficulties and potential avenues for creating new platforms to identify peptide agents using organoid models.

show abstract

“…[144][145][146][147][148] However, the high diversity of nature product peptides poses a challenge to the identification of the tumor neoantigens mentioned above and bioactive peptides derived from venoms, which are produced by many kinds of organisms, such as plants, snakes, spiders, and insects, and are found to interact with tumors and modulate the proliferation, migration, immune response of tumor cells, suggesting potential therapeutic agents for cancers. [149][150][151][152][153][154][155] Therapeutic peptides are promising candidates for treating various diseases, and more effective peptide drugs are required to address clinical demands. Thus, high-throughput screening of therapeutic peptides using organoid technology may significantly improve the efficiency for identifying and uncovering the optimal peptides with high binding affinity and ideal therapeutic effects.…”

Section: Perspective and Challenges Of Organoid-based High-throughput...mentioning

confidence: 99%

“…For example, the expression of immune checkpoint proteins (PD‐1 and PD‐L1) can be suppressed by targeted peptides to increase the immune response to kill tumor cells 144–148 . However, the high diversity of nature product peptides poses a challenge to the identification of the tumor neoantigens mentioned above and bioactive peptides derived from venoms, which are produced by many kinds of organisms, such as plants, snakes, spiders, and insects, and are found to interact with tumors and modulate the proliferation, migration, immune response of tumor cells, suggesting potential therapeutic agents for cancers 149–155 . Therapeutic peptides are promising candidates for treating various diseases, and more effective peptide drugs are required to address clinical demands.…”

Section: Perspective and Challenges Of Organoid‐based High‐throughput...mentioning

confidence: 99%

Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening

Zhang,

Shen,

Wang

et al. 2023

VIEW

View full text Add to dashboard Cite

Organoids are three‐dimensional cell aggregates with near‐physiologic cell behaviors and can undergo long‐term expansion in vitro. They are amenable to high‐throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid‐based high‐throughput screening has been extensively employed to discover small‐molecule drugs, encompassing the steps of generating organoids, examining efficient drugs in organoid cultures, and data assessment. Compared to small molecules, peptides are more straightforward to synthesize, can be modified chemically, and demonstrate high target specificity and low cytotoxicity. Therefore, they have emerged as promising carriers to deliver drugs to disease‐associated targets and could be efficient therapeutic drugs for various diseases. To date, organoids have been used to evaluate the efficacy of certain peptide agents; however, no organoid‐based high‐throughput screening of peptide drugs has been reported. Given the advantages of peptide drugs, there is an urgent need to establish organoid‐based peptide high‐throughput screening platforms. In this review, we discuss the typical approach of screening small‐molecular drugs with the use of organoid cultures, as well as provide an overview of the studies that have incorporated organoids in peptide research. Drawing on the knowledge from small molecular screens, we explore the difficulties and potential avenues for creating new platforms to identify peptide agents using organoid models.

show abstract

Bioactive peptides from venoms against glioma progression

Cited by 8 publications

References 143 publications

Development of glioblastoma organoids and their applications in personalized therapy

Development of glioblastoma organoids and their applications in personalized therapy

Integration of organoids in peptide drug discovery: rise of the high-throughput screening

Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening

Contact Info

Product

Resources

About